Light Switch Wakes Sleeping Cancer Cells and Makes Them Vulnerable Again
ETH Zurich scientists have created a light-controlled molecular switch that can selectively destroy dormant cancer cells by targeting the receptors responsible for their survival mode triggered by stress hormones.
Cancer Cell Dormancy Problem
Some cancer cells evade treatment by entering a dormant state triggered by stress hormones. ETH Zurich scientists have created a light-controlled molecular switch that selectively destroys the receptors responsible for this survival mode. This breakthrough addresses one of oncology's most persistent challenges: treatment-resistant cancer cells that hide from chemotherapy and radiation.
The Molecular Switch Technology
The innovation uses optogenetics—the ability to control biological processes with light—to target specific cellular receptors. By illuminating dormant cancer cells with light, researchers can activate the molecular switch to destroy the protective mechanisms that allow these cells to survive standard cancer treatments. This approach is highly selective, potentially reducing damage to healthy tissues compared to conventional therapies.
Clinical Significance
Cancer cells that enter dormancy are responsible for recurrence and metastasis. By making dormant cells vulnerable again, this technology could prevent tumor regrowth and improve long-term survival rates. The approach is particularly promising because it combines precision targeting with a non-invasive light stimulus, offering potential for real-time control during treatment.
Path Forward
The next steps involve testing this technology in animal models and developing clinical protocols for human trials. Researchers aim to integrate the light-controlled switch into existing cancer treatment frameworks, potentially transforming how oncologists approach treatment-resistant cancers in the coming years.